News

Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024

News 22.10.2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and PARIS, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, and Orano Med, a clinical-stage radiopharmaceutical...

read more

Topadur Pharma AG Strengthens Executive Team Towards IPO

News 18.10.2024 Topadur Pharma AG, a Swiss clinical-stage biotechnology company, today announces the appointments of PD Dr. Matthias Schäfer as Chief Innovation Officer (CIO) and Prof. Dr. Jay Siegel as Chief Research Officer (CRO). Matthias Schäfer is a seasoned international leader, who uniquely combines management skills with in-depth experience in biomedical research from...

read more

FDA Fast Track Designation for ALXN2220 for Depletion of Cardiac ATTR

News 16.10.2024 Zurich, Switzerland - 14.10.2024 Neurimmune today announced that the U.S. Food and Drug Administration (FDA) has granted Alexion, AstraZeneca Rare Disease Fast Track designation for the development of ALXN2220 (formerly NI006) for the treatment of transthyretin amyloidosis with cardiomyopathy (ATTR-CM). ATTR-CM is a systemic, progressive and life-threatening disease caused by the deposition of...

read more